Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Calcium Channel
    (14)
  • Potassium Channel
    (3)
  • Carbonic Anhydrase
    (1)
  • Chloride channel
    (1)
  • Endogenous Metabolite
    (1)
  • HDAC
    (1)
  • IL Receptor
    (1)
  • Interleukin
    (1)
  • Sodium Channel
    (1)
  • Others
    (11)
Filter
Search Result
Results for "

T-channels

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    34
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    5
    TargetMol | Peptide_Products
  • Natural Products
    1
    TargetMol | Natural_Products
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
  • Isotope Products
    2
    TargetMol | Isotope_Products
Zonisamide
AD 810, CI 912
T026768291-97-4
Zonisamide (AD 810), a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may lower the uptake of the inhibitory neurotransmitter GABA while increasing the uptake of the excitatory neurotransmitter glutamate.
  • Inquiry Price
Size
QTY
1-Octanol
Octanol
T10024111-87-5
1-Octanol, a saturated fatty alcohol, functions as an inhibitor of T-type calcium channels (T-channels), showing an inhibitory concentration (IC50) of 4 μM for native T-currents[1]. Additionally, 1-Octanol is recognized for its potential as a biofuel, possessing diesel-like properties[2].
  • Inquiry Price
Size
QTY
Lomerizine dihydrochloride
Terranas, Lomerizine 2HCl, Lomerizine hydrochloride, KB-2796
T6571101477-54-7
Lomerizine dihydrochloride (KB-2796) is an antagonist of L- and T-type voltage-gated calcium channels used to treat migraine.
  • Inquiry Price
Size
QTY
Atagabalin
PD 0200390,PD-0200390,PD0200390
T30188223445-75-8In house
Atagabalin, also known as PD 0200390, is a gabamimetic agent under development for the treatment for insomnia. Atagabalin is related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was discontinued following unsatisfactory t
  • Inquiry Price
Size
QTY
T16Ainh-A01
T13059552309-42-9
T16Ainh-A01 is a potent inhibitor of TMEM16A Chloride channel, inhibiting TMEM16A-mediated chloride currents (IC50 of 1 µM),and functions as a calcium-activated chloride channel (CaCC).
  • Inquiry Price
Size
QTY
ICILIN
AG-3-5
T181436945-98-9
ICILIN (AG-3-5) is a synthetic TRPM8 ion channel super-agonist.
  • Inquiry Price
Size
QTY
Mibefradil
Ro 40-5967
TQ0153116644-53-2
Mibefradil is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels (IC50s: 2.7 μM and 18.6 μM for T-type and L-type currents).
  • Inquiry Price
10-14 weeks
Size
QTY
Efonidipine
(±)-Efonidipine, NZ-105
T2323111011-63-3
Efonidipine (NZ-105)(NZ-105) is a dihydropyridine calcium channel blocker, blocking both T-type and L-type calcium channels.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
UK 78282 hydrochloride
T23497136647-02-4
UK 78282 hydrochloride, a novel potent and selective Kv1.3 blocker.UK 78282 hydrochloride inhibits Kv1.3 voltage-gated potassium channels and suppresses human T cell activation.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
Trimethadione
3,5,5,-Trimethyloxazolidine-2,4-dione
T0283127-48-0
Trimethadione (3,5,5-Trimethyloxazolidine-2,4-dione) is a dione-type anticonvulsant with antiepileptic activity.
  • Inquiry Price
Size
QTY
Mibefradil dihydrochloride
Ro 40-5967 (dihydrochloride)
T12032116666-63-8
Mibefradil dihydrochloride (Ro 40-5967 (dihydrochloride)) is an blocker of calcium channel with moderate selectivity for T-type Ca2+ channels (T-type and L-type currents with IC50s of 2.7 μM and 18.6 μM, respectively).
  • Inquiry Price
Size
QTY
ML218 hydrochloride
T120762319922-08-0
ML218 hydrochloride is a selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor (Cav3.2 and Cav3.3 with IC50s of 310 nM and 270 nM , respectively).
  • Inquiry Price
6-8 weeks
Size
QTY
ML218
T12076L1346233-68-8
ML218 is an orally active, selective, potent, and blood-brain barrier-crossing inhibitor of T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) (IC50 for Cav3.2 and Cav3.3 is 310 nM and 270 nM, respectively).ML218 inhibits the burst activity of neurons in the subthalamic nucleus (STN).
  • Inquiry Price
6-8 weeks
Size
QTY
NMP-7
NMP7,NMP 7
T258741358039-07-2
NMP-7 is a non-selective CB1 and CB2 cannabinoid receptor agonist that works by blocking T-type calcium channels.
  • Inquiry Price
6-8 weeks
Size
QTY
Z944
Z 944, Z-944
T292011199236-64-0
Z944 is a T-type calcium channel blocker. Z944 delays the progression of seizures in the amygdala kindling model. Z944 disrupts prepulse inhibition in both epileptic and non-epileptic rats.
  • Inquiry Price
Size
QTY
n-arachidonoyl taurine
T35918119959-65-8
N-Arachidonoyl taurine is an arachidonoyl amino acid. It is oxygenated by 12(S)- and 15(S)-lipoxygenase and is converted to 12-HETE-taurine (12-HETE-T) in murine resident peritoneal macrophages. N-Arachidonoyl taurine is an activator of the transient receptor potential vanilloid (TRPV) channels TRPV1 and TRPV4 (EC50s = 28 and 21 μM, respectively). It increases calcium flux in HIT-T15 pancreatic β-cells and INS-1 rat islet cells when used at a concentration of 10 μM and increases insulin secretion from 832 13 INS-1 pancreatic β-cells. The levels of N-arachidonoyl taurine are changed in mouse brain following administration of δ9-tetrahydrocannabinol (δ9-THC).
  • Inquiry Price
Size
QTY
(±)5(6)-EET
T3607087173-80-6
5(6)-EET is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5(6)-EET degrades into 5,6-DiHET and 5(6)-δ-lactone, which can be converted to 5(6)-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5(6)-EET has been implicated in the mobilization of calcium and hormone secretion. 5(6)-EET is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50 = 0.54 μM), and Cav3.3 and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5(6)-EET is provided as a mixture of the free acid and lactone.
  • Inquiry Price
Size
QTY
(2R/S)-6-PNG
6-Prenylnaringenin, (±)-6-Prenylnaringenin
T3742768682-01-9
(2R S)-6-PNG (6-Prenylnaringenin) is a novel natural histone deacetylase inhibitor with anticancer and antitumor activity, and it blocks T-type calcium channels to reduce neuropathic and visceral pain in mice.
  • Inquiry Price
6-8 weeks
Size
QTY
Zonisamide-13C2,15N
Zonisamide-13C2,15N
T378471188265-58-8
Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid or dihydroxyphenyl acetic acid , and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy. |1. Masuda, Y., Ishizaki, M., and Shimizu, M. Zonisamide: Pharmacology and clinical efficacy in epilepsy. CNS Drug Rev. 4(4), 341-360 (1998).|2. Rock, D.M., Macdonald, R.L., and Taylor, C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 3(2), 138-143 (1989).|3. Suzuki, S., Kawakami, K., Nishimura, S., et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12(1), 21-27 (1992).|4. Nishimori, I., Vullo, D., Minakuchi, T., et al. Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from Helicobacter pylori. Bioorg. Med. Chem. Lett. 16(8), 2182-2188 (2006).|5. De Simone, G., Di Fiore, A., Menchise, V., et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 15(9), 2315-2320 (2005).|6. Yabe, H., Choudhury, M.E., Kubo, M., et al. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J. Pharmacol. Sci. 110(1), 64-68 (2009).
  • Inquiry Price
Size
QTY
Suvecaltamide
MK-8998
T5632953778-58-0
Suvecaltamide (MK-8998) as potent inhibitors of T-type calcium channels.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
IAA65
T613932987139-96-6
IAA65 is a potent inhibitor of T-type calcium channels, exhibiting an IC50 value of 18.9 μM, and holds potential for use in epilepsy research [1].
  • Inquiry Price
10-14 weeks
Size
QTY
TTA-P1
T61747918333-06-9
TTA-P1 is a highly potent compound that effectively inhibits human T-type calcium channels, which are involved in various physiological processes such as neuronal burst firing, hormone secretion, and cell growth. With its unique state-independent properties, TTA-P1 holds promising potential for advancing research on absence epilepsy [1].
  • Inquiry Price
10-14 weeks
Size
QTY
TTA-P2
T624021072018-68-8
TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-type calcium channels. It effectively penetrates the CNS and blocks natural T-type currents in deep cerebellar nucleus neurons, completely eliminating window currents in wild-type and mutant Cav3.1 channels. [research]
  • Inquiry Price
6-8 weeks
Size
QTY
Cav 3.2 inhibitor 2
T63606
Cav 3.2 inhibitor 2 is an inhibitor of Cav3.2 T-type Ca2+channels with an IC50=0.09339 μM at a constant potential of -80 mV. Cav 3.2 inhibitor 2 exhibits potent inhibition of T-channel-dependent somatic and visceral pain in mice. inhibitor 2 can be used to study intractable pain.
  • Inquiry Price
10-14 weeks
Size
QTY